Stockscreener 앱 받기
1.11
13.71%
0.1338
시간 외 거래:
1.11
전일 마감가:
$0.9762
열려 있는:
$0.9558
하루 거래량:
3.09M
Relative Volume:
0.62
시가총액:
$32.50M
수익:
$1.44M
순이익/손실:
$-21.34M
주가수익비율:
-0.8302
EPS:
-1.3371
순현금흐름:
$-17.38M
1주 성능:
+37.21%
1개월 성능:
+98.21%
6개월 성능:
+41.40%
1년 성능:
-35.09%
1일 변동 폭
$0.9251
$1.14
1주일 범위
$0.82
$1.22
52주 변동 폭
$0.475
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
명칭
Longeveron Inc
전화
305-302-7158
주소
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.11 | 28.58M | 1.44M | -21.34M | -17.38M | -1.3371 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
Longeveron Inc 주식(LGVN)의 최신 뉴스
Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript - Insider Monkey
Longeveron's third-quarter 2026 HLHS trial outcomes may confirm the viability of its overall business approach—while its Alzheimer's program continues to divert focus - Bitget
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure - TipRanks
Longeveron (LGVN) shares surge on $30 million private placement deal - MSN
Longeveron Earnings Call: Pivotal Trials, Tight Cash - TipRanks
Insider Buy: Will Longeveron Inc benefit from rising consumer demand2026 Trading Volume Trends & Growth Oriented Trading Recommendations - baoquankhu1.vn
Treasury Yields: Is Longeveron Inc stock a value trap2026 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
LGVN shares rise after investigational therapy shows improvement in age-related frailty in study - MSN
Longeveron Inc. 2026 10-K: Clinical-Stage Biotech Advancing Laromestrocel (Lomecel-B) for Regenerative Medicine and Intellectual Property Expansion - Minichart
Longeveron Funding & Clinical Strategy: ELPIS II Results Expected Q3 2026News and Statistics - IndexBox
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Longeveron (LGVN) Q4 2025 Earnings Call Transcript - AOL.com
Longeveron braces for Q4 results following recent funding boost - MSN
Longeveron Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - BioSpace
Earnings Call Summary | Longeveron(LGVN.US) Q4 2025 Earnings Conference - 富途牛牛
LGVN: $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses - TradingView
Earnings call transcript: Longeveron reports Q4 2025 loss, raises capital By Investing.com - Investing.com Canada
Earnings call transcript: Longeveron reports Q4 2025 loss, raises capital - Investing.com
LONGEVERON ($LGVN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
LGVN: Revenue fell 50% and net loss rose 41% in 2025, with pivotal HLHS trial results due Q3 2026 - TradingView
LGVN: 2025 net loss widened to $22.7M on lower revenue and higher R&D, with cash needs persisting - TradingView
Longeveron 10-K: Revenues $1.199M, Net Loss $(22.7)M - TradingView
Longeveron Inc. Announces Resignation of Richard Kender from the Board of Directors and Audit Committee, Effective March 2026 - marketscreener.com
Longeveron (NASDAQ: LGVN) advances laromestrocel cell therapy across HLHS and Alzheimer’s - Stock Titan
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Longeveron Braces For Q4 Results Following Recent Funding Boost - Benzinga
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Dividend Watch: Is Privia Health Group Inc stock overvalued or fairly pricedWeekly Investment Report & Community Verified Trade Alerts - baoquankhu1.vn
LGVN Longeveron Inc. (NASDAQ) pre-market 17 Mar 2026: Q4 earnings catalyst - Meyka
Longeveron’s Stem Cell Therapy Boosts Physical Function, Spurs Market Interest - timothysykes.com
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Longeveron Hits Milestones in Phase 2b Trial and CEO Transition - timothysykes.com
Longeveron Stock on a Rollercoaster: Clinical Trials and CEO Appointment Fuel Market Interest - StocksToTrade
LGVN Longeveron Inc. (NASDAQ) +20% to $0.97 Mar 13, 2026: earnings, runway - Meyka
Zacks Research Predicts Increased Earnings for Longeveron - Defense World
Longeveron Expands CEO Roster Amid Positive Phase 2 Trial Outcomes - StocksToTrade
Longeveron (LGVN) CEO discloses no beneficial share ownership - Stock Titan
Longeveron Announces $30 Million Private Placement Financing - TipRanks
Best Biotech Stocks To Keep An Eye On – March 10th - Defense World
Longeveron closes $15 million financing, extends runway to 4Q26 - Investing.com Australia
Longeveron (NASDAQ: LGVN) closes $15.9M raise with up to $15M more - Stock Titan
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 - Bitget
Biotech Longeveron to reveal 2025 results in March 17 call - Stock Titan
Longeveron closes $15 million financing, extends runway to 4Q26 By Investing.com - Investing.com South Africa
Longeveron Announces Closing of Private Placement of up to $30 Million - Bitget
Biotech Longeveron secures $15M, cash runway past 2026 HLHS trial readout - Stock Titan
A $30 Million Reason to Buy Penny Stock Longeveron Today - Yahoo Finance
Longeveron secures $15M financing with potential for additional $15M tied to trial milestones - MSN
Longeveron secures $15M financing, eyes $15M more on trial results By Investing.com - Investing.com Canada
Longeveron Inc (LGVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Longeveron Inc 주식 (LGVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
1.20%
0.06%
자본화:
|
볼륨(24시간):